glp 1 drugs kidney disease Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria Glucagon-Like Peptide-1 Receptor Agonist Use

[1] [2] Traditionally administered via subcutaneous injection, some research has explored transdermal patch delivery systems as an alternative route of administration

Another factor is FGF21 produced by BAT and BeAT, which enhances the browning of WAT and increases fatty acid oxidation by increasing the expression of UCP1 and CIDEA to promote thermogenesis and improve energy balance [86,87,88]

Competing interests DG received honoraria for speaking at meetings from Novartis, Sanofi, Eli Lilly and Company, AstraZeneca, and Novo Nordisk

The scope of the review is intentionally selective rather than exhaustive, focusing on peptidereceptor systems that demonstrate biological plausibility, mechanistic coherence, and unmet therapeutic potential, yet lack approved therapeutic analogs or advanced clinical programs

Known side effects include nausea, vomiting, and abdominal discomfort

To know which diabetes drug is best for you, talk with your doctor